Daniel DeAngelo, MD, PhD, is the Chief Physician in the Division of Leukemia, and Professor of Medicine at the Dana-Farber Cancer Institute, part of Harvard Medical School, Boston, MA.
Prof. DeAngelo completed his medical training at Albert Einstein College of Medicine, NY, in 1993, followed by a residency at Massachusetts General Hospital, in Boston. He then undertook a Clinical Fellowship at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he joined the staff in 1999. Since, Prof. DeAngelo has been involved in clinical protocols designed to treat patients with AML, ALL, and CML, and has authored/co-authored over 200 peer-reviewed publications.
Prof. DeAngelo is actively involved with the American Society of Hematology and the American Society of Clinical Oncology, as well as serving as a member of the NCCN chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) guidelines committees.
Speaking on hematological malignancies and CAR-T therapy
Prof. DeAngelo’s research interests include novel immunotherapeutic approaches for the treatment of leukemia, especially acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He has a particular interest in developing a leukemia tumor vaccine from patients with AML or MDS, and has been involved in trialling new treatments, and new combinations of treatments, for multiple types of leukemia.